The 1st year of the COVID-19 epidemic in Estonia: an interrupted time series of population based nationwide cross-sectional studies

Author:

Uusküla AnneliORCID,Kalda Ruth,Solvak Mihkel,Jürisson Mikk,Käärik Meelis,Fischer Krista,Keis Aime,Raudvere Uku,Vilo Jaak,Peterson Hedi,Käärik Ene,Metspalu Mait,Jürgenson Tuuli,Milani Lili,Kolberg Liis,Tiit Ene-Margit,Vassil Kristjan

Abstract

AbstractBackgroundDecisions about the continued need for control measures and the effect of introducing COVID-19 vaccinations rely on accurate and population-based data on SARS-CoV-2 positivity and risk factors for testing positive.MethodsIn this interrupted time series of population-based nationwide cross-sectional studies, data from nasopharyngeal testing and questionnaires were used to estimate the SARS-CoV-2 RNA prevalence and factors associated with test positivity over the 1st year of the COVID-19 epidemic.The study is registered with the ISRCTN Registry, ISRCTN10182320.ResultsBetween April 23, 2020 and February 2, 2021, results were available from 34,915 individuals and 27,870 samples from 11 consecutive studies. The percentage of people testing positive for SARS-CoV-2 decreased from 0.27% (95% CI 0.10% - 0.59%) in April to 0.04% (95% CI 0.00% - 0.22%) by the end of May and remained very low (0.01%, 95% CI 0.00% - 0.17%) until the end of August, followed by an increase since November (0.37%, 95% CI 0.18% - 0.68%) that escalated to 2.69% (95% CI 2.08% - 2.69%) in January 2021. In addition to substantial change in time, an increasing number of household members (for one additional OR 1.15, 95% CI 1.02-1.29), reporting current symptoms of COVID-19 (OR 2.21, 95% CI 1.59-3.09), and completing questionnaire in the Russian language (OR 1.85, 95% CI 1.15-2.99) were associated with increased odds for SARS-CoV-2 RNA positivity.ConclusionsSARS-CoV-2 population prevalence needs to be carefully monitored as vaccine programmes are rolled out in order to inform containment decisions.Strengths and limitations of this studyOur study relies upon nation-wide and population-based data on SARS-CoV-2 prevalence, and presents changes in prevalence over the whole 1st year of the Covid-19 epidemic.Our analysis of SARS-CoV-2 infection risk factors is not limited to notification or health care-based case data.Selection bias may have been introduced as a result of low response rate. The direction of bias is unclear, but most likely operates rather uniformly over the period of observation, though this presents less of a threat to the SARS-CoV-2 prevalence trend analysis.Our data could be used to adequately project the future course of the SARS-CoV-2 epidemic and the effect of control measures.

Publisher

Cold Spring Harbor Laboratory

Reference40 articles.

1. WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11. March 2020. https://www.who.int/dg/speeches/detail/ (accessed on 18.09.2020)

2. Coronavirus resource center. https://coronavirus.jhu.edu/map.html (accessed 18.03.2021)

3. Koroonakaart 30.01.2021 andmed. https://koroonakaart.ee/en (accessed on March 22, 2021).

4. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years

5. Clinical Characteristics of Coronavirus Disease 2019 in China

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3